|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||169.9100 - 172.3500|
|52 Week Range||148.3100 - 181.9200|
|PE Ratio (TTM)||70.58|
|Beta (3Y Monthly)||0.96|
|Expense Ratio (net)||0.10%|
The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.
Author Evan McCulloch Senior Vice President, Director of Research Franklin Equity Group® Portfolio Manager, Franklin Biotechnology Discovery Fund Since hitting an all-time high in July 2015, biotech stocks, as measured by the NASDAQ Biotechnology ...
Internet retail, small-cap and a health care stock fund are among SFMG Wealth Advisor's top ETF picks for the coming months.
The solid performance of the healthcare market in the first eight months of 2018 has created investment opportunities. These ETFs are poised to take advantage.
Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.
The healthcare sector and related ETFs have been among the best performing defensive plays this year as strong earnings and potential Trump administration actions on drug pricing drew greater investment ...
The healthcare sector is one of this year's best-performing sectors and the group's recent strength is luring some investors to the related exchange traded funds. For healthcare ETFs, the good news is that the U.S. economy moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up. “The $8.2 billion Vanguard Health Care ETF, known by its ticker VHT, had 1.6 million shares worth $272 million trade Monday, record one-day turnover for the fund.
With the healthcare sector recently outperforming technology, investors have been embracing healthcare exchange traded funds. The Health Care Select Sector SPDR (XLV) is the largest healthcare ETF by assets. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
The month of August started off on a shaky note for Wall Street with Fed imposed rising rate concerns and severity in the U.S.-Sino trade relations coming to the forefront.The Trump administration is reportedly considering a hike in tariffs from 10% to 20% on $200 billion worth of Chinese goods, after a 25% tariff announcement on $50 billion worth of goods.Source: Shutterstock
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.
Allergan’s (AGN) US General Medicines segment includes revenues from the US sales of its central nervous system products, women’s health products, gastrointestinal products, anti-infective products, and diversified brands.
The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.
Analysts expect Merck & Co.’s (MRK) revenues to increase ~7.1% to $10.1 billion in 1Q18, compared to revenues of $9.4 billion in 1Q17. Revenues for 1Q18 are expected to have a positive impact on growth in operating revenues and a favorable impact from foreign exchange.
Allergan (AGN) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues today. It reported EPS of $3.74 on revenues of $3.7 billion, compared to EPS of $3.36 on revenues of $3.6 billion in 1Q18.
Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer (PFE) is set to release its 1Q18 earnings on May 1, 2018. Wall Street analysts estimate Pfizer will report earnings per share (or EPS) of $0.74 on revenues of $13.1 billion for 1Q18.
About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.
When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. For some ETFs and funds, the definition of low-cost retirement funds is relative.